PROJECT SUMMARY
Lyme disease (LD), caused by the tick-borne bacteria Borrelia, is the most common vector-borne infectious
disease in the US with 300,000 new cases annually. If diagnosed early and treated with appropriate antibiotics,
outcomes for LD are typically excellent, but delays in treatment result in arthritis, carditis, or neuroborreliosis.
The most telling manifestation of early LD is the erythema migrans (EM); however, the EM is often difficult to
distinguish from an allergic reaction, and 50% of those infected never develop the rash. Displaying non-specific
symptoms which mimic those of other diseases, LD can only be confirmed by laboratory tests. Current
laboratory tests rely on serological methods which are ineffective at diagnosing early LD and cannot distinguish
between an active and previous infection. Molecular diagnostic tests for direct detection of Borrelia from blood
continue to demonstrate poor performance. The end result is that no test can detect early LD with confidence.
To address this unmet need, HelixBind has developed RaPID/LD; a fully automated, ultra-sensitive test
specifically designed for the direct detection of Borrelia from whole blood. RaPID/LD displays a limit of detection
that is roughly two orders of magnitude more sensitive than existing molecular diagnostics. RaPID/LD will only
detect active infections and incorporates a broad menu of Borrelia species. The assay has undergone preliminary
analytical verification studies and has been assessed with clinical specimens. As a result of the demonstrated
capabilities, RaPID/LD was selected as a Phase I winner of the US Dept of HHS's LymeX Diagnostics Prize.
This proposal focuses on completing the tasks required to directly support commercialization of RaPID/LD
through key verification and validation efforts required to launch the test. To ensure success in this project, we
have assembled a world-class team of experts. Combined our team has deep technical expertise in assay
development, microbiology, Borrelia infections, and molecular diagnostics. Our team members have been
instrumental in developing multiple in-vitro diagnostic platforms and over 30 commercial in-vitro diagnostic
assays, and combined with our internal regulatory expertise, has necessary experience and capabilities to ensure
that all milestones will be met.
